Brokers Offer Predictions for Immatics FY2025 Earnings

Immatics (NASDAQ:IMTX) – Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Immatics in a research note issued on Tuesday, April 1st. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($1.53) per share for the year, down from their prior estimate of ($1.34). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

Immatics Stock Up 4.3 %

Shares of NASDAQ:IMTX opened at $4.17 on Thursday. The company’s fifty day moving average is $4.89 and its two-hundred day moving average is $7.29. The company has a market cap of $497.71 million, a P/E ratio of -6.32 and a beta of 0.83. Immatics has a 12-month low of $3.88 and a 12-month high of $13.77.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million.

Institutional Investors Weigh In On Immatics

Several hedge funds have recently bought and sold shares of IMTX. Bank of America Corp DE boosted its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC lifted its position in Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock worth $68,000 after buying an additional 2,479 shares in the last quarter. Quarry LP boosted its stake in shares of Immatics by 29.4% during the 3rd quarter. Quarry LP now owns 11,000 shares of the company’s stock valued at $126,000 after buying an additional 2,500 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Immatics by 24.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after acquiring an additional 4,477 shares in the last quarter. Finally, Forefront Analytics LLC raised its holdings in shares of Immatics by 42.3% during the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company’s stock worth $113,000 after acquiring an additional 4,731 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.